Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IASLC TTLC 2024 | Management options for patients with type II/III BRAF-mutated lung cancer

Rajwanth Veluswamy • 20 Feb 2024
IASLC TTLC 2024
Lung Cancer

Rajwanth Veluswamy, MD, Icahn School Of Medicine At Mount Sinai, New York, NY, discusses treatment strategies for patients with type II or III BRAF-mutated lung cancer. Dimer specific inhibitors exist for these patients and Dr Veluswamy gives an overview of the disease biology behind the dimerization process. Immunotherapy additionally has a potential role, as these tumors are immunogenic. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rajwanth Veluswamy

Evaluating the role of pan-RAF inhibitors in RAF and RAS mutant tumors
2:07
Evaluating the role of pan-RAF inhibitors in RAF and RAS mutant tumors
Rajwanth Veluswamy • 20 Feb 2024
An introduction to the MAPK signaling pathway and pan-RAF inhibitors
8:06
An introduction to the MAPK signaling pathway and pan-RAF inhibitors
Rajwanth Veluswamy • 20 Feb 2024
Real-world data to account for lack of elderly patients with NSCLC in clinical trials
1:17
Real-world data to account for lack of elderly patients with NSCLC in clinical trials
Rajwanth Veluswamy • 8 Aug 2022
First-line treatment decision making for elderly patients with NSCLC
2:14
First-line treatment decision making for elderly patients with NSCLC
Rajwanth Veluswamy • 8 Aug 2022

Related Videos

AI decision support in EGFR-mutant metastatic non-small cell lung cancer
3:12
AI decision support in EGFR-mutant metastatic non-small cell lung cancer
Chinmay Jani • 31 May 2026
The value of ctDNA biomarkers in colorectal and non-small cell lung cancer
1:15
The value of ctDNA biomarkers in colorectal and non-small cell lung cancer
Erika Ruiz-Garcia • 1 Jun 2026
FLAME: osimertinib plus chemotherapy in persistent ctDNA EGFR-mutant NSCLC
1:15
FLAME: osimertinib plus chemotherapy in persistent ctDNA EGFR-mutant NSCLC
Erika Ruiz-Garcia • 1 Jun 2026
Real-world survival outcomes with atezolizumab versus durvalumab in extensive-stage SCLC
1:39
Real-world survival outcomes with atezolizumab versus durvalumab in extensive-stage SCLC
Apar Ganti • 30 May 2026
The content of VJOncology is intended for healthcare professionals